Gooderham, M., Spelman, L., Imafuku, S., Romanelli, M., Merola, J. F., Armstrong, A. W., Colston, E., Banerjee, S., Scharnitz, T. and Blauvelt, A. (2023) “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials”, SKIN The Journal of Cutaneous Medicine, 7(4), p. s219. doi: 10.25251/skin.7.supp.219.